Research Staff Perspectives on Cancer Clinical Trials and Barriers to Recruitment: A Qualitative Research

Amany R. Keruakous (amany-keruakous@ouhsc.edu)  
OUHSC: The University of Oklahoma Health Sciences Center  
https://orcid.org/0000-0002-7205-3975

Silas Day  
OUHSC: The University of Oklahoma Health Sciences Center

Kenny D. Garcia-Ramiu  
OUHSC: The University of Oklahoma Health Sciences Center

Melissa Yarbrough  
OUHSC: The University of Oklahoma Health Sciences Center

Adam S. Asch  
OUHSC: The University of Oklahoma Health Sciences Center

Research note

Keywords: Qualitative methodology, Research staff perspective, Cancer clinical trials, Barriers to clinical trials enrollment, Proposed interventions to improve clinical trials accrual

Posted Date: March 18th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-322279/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Study objectives

-Highlight common barriers to recruiting adults’ cancer patients, encountered by research coordinators from all disease sites

-Propose effective solutions to identified barriers.

Results

We are reporting our results of a qualitative research methodology investigating barriers to clinical trials enrollment from a new perspective. The most commonly reported obstacles, for clinical trials enrollment, from our research staff perspective were categorized into five themes: clinical trials protocol, communication barriers and cultural beliefs, financial barriers, patients’ comorbidities and performance status, and physicians’ commitment. Assessing barriers encountered by clinical research staff is infrequently used as a metric for improving clinical trial enrollment, but provides important perspective. Interventions to improve clinical trial feasibility and accrual are critical to improve cancer care.

Introduction

Clinical trials provide the foundation on which advances in cancer therapies are built, but so much stands in the way. While clinical trial treatment is on-guideline with potentially lower financial burden to patients, the national average of cancer patients accrued to clinical trials remains 2-4% (1, 2).

Poor accrual cancer clinical trials has been chronic problem in academic as well as community-based practices (3-6). Furthermore, a large number of clinical trials in oncology close early due to poor accrual. In an analysis of clinical trials for adults registered on Clinicaltrials.gov, researchers concluded, 20% of the trials fail to accrue (7).

Reasons reported to be common obstacles for accrual in clinical trials are often investigated independently a) financial barriers (8), b) patient-reported factors (9, 10), c) physician-related factors (11), d) barriers encountered by selected patient population (12-16), or e) selected disease sites (17, 18).

Understanding the etiology of low patient accrual is necessary to improve participation in clinical trials. Researchers have attempted to identify the barriers to clinical trial enrollment by questioning individuals eligible for participation in clinical trials (9, 19), physicians involved (10, 20, 21), or by exploring lessons from failed accruals (22).

The Stephenson Cancer Center, the only NCI designated cancer center in the state of Oklahoma, has led accrual to NCI-LAPS trials over the past four years. The Stephenson Cancer Center also fields’ numerous investigator-initiated and industry-sponsored trials.
In this study, we sought to identify common obstacles for trial accrual from a new perspective. We surveyed our clinical research staff—specifically our research coordinators, patient's primary point of contact in the process of recruitment, screening, consenting, data collection, and compliance.

The purpose of this study is to a) highlight common barriers to recruiting cancer patients, encountered by research coordinators, and b) propose effective solutions to identified barriers.

**Materials And Methods**

- **Study design and participants**

This study is a prospective qualitative study, using Grounded Theory Methodology (23, 24). Given the lack of data on barriers encountered by research staff members during the patient's enrollment process in clinical trials; we thought that the qualitative method is appropriate for the study as we are exploring a new perspective by using inductive reasoning with data collection and interpretation to construct a theory.

The grounded theory method was felt to be fit for the research question as it addresses their experience and interactions with the patients to identify and categorize barriers to clinical trial enrollment to develop a theory from the analysis grounded in the data provided.

To achieve purposive sampling, we choose participants working in a direct relationship with cancer patients from all disease sites and serving a wide diversity of patients. Thus, we focused on the research staff that involved in interventional clinical trials.

Participants for this qualitative study were approached via email “formal survey” (supplemental material 1) which asked open-ended questions to procure frequently encountered obstacles that survey participants meet during their daily interactions with patients. The number of participants was determined by reaching point of data saturation (i.e., no more new themes emerging).

- **Data collection**

Data collected through a survey that was sent via e-mail to describe the following: 1) the disease site they are primarily involved 2) what is their role in clinical trials (data management, compliance, etc.) 3) what percentage of screened patients decline participation in the clinical trial 4) What are the most common reasons that patients decline participation? 5) What are the main obstacles to enrollment? 6) Additional comments (where they had the opportunity to describe any additional information and suggestions, in addition to the semi-structured interviews).

- **Data analysis:**

De-identified Surveys and follow-up transcribed meetings were collected in one software. Data were categorized into codes creating a codebook to ensure inter-coding agreement. Emerging codes were then
discussed and agreed upon by team members. Emerging codes led to themes. The process of defining and refining the themes was continuous throughout the data analysis.

Selected research coordinators were asked to review the data collected and the manuscript to ensure confirmability.

**Results**

- **Sample**

Twenty-one surveys were received from research coordinators at different disease sites. Of these 21, 6 surveys were from gynecologic malignancies, 5 from breast oncology, 3 from lung and head/neck malignancies, 4 from malignant hematology, 2 from gastrointestinal malignancies, and one from genitourinary malignancies.

- **Themes**

Five main themes important to clinical trial enrollment were identified: clinical trials protocol, communication barriers and cultural beliefs, financial barriers, patients' comorbidities and performance status, and physicians' commitment. Below we will describe the themes. Illustrative quotes are provided in Table 1.

- **Clinical trial protocol:**

A common obstacle encountered by our research coordinators pertains to the clinical trial schema and protocol requirements. Participants frequently reported that the inclusion and exclusion criteria are often overly strict. Furthermore, patients commonly tend to refuse to participate in clinical trials if additional biopsies are required.

Also, frequent laboratory testing and office visits often drive patients away from participation in clinical trials, concerns for affecting their work schedule and increase the time-off work to participate in such activities, especially if they live at a distance from the treating institution. Patients prefer a more flexible approach to treat their condition and preserve quality of life.

- **Communication barrier and Cultural beliefs**

Frequently reported, the communication barrier has been one of the difficult obstacles to overcome. If the patient is speaking a non-English language, commonly Spanish, that often excludes them from participating in clinical trials. The absence of language appropriate consent or the need to requesting institutional review board (IRB) approval of Spanish informed consent delays the enrollment procedure, the urgency to starting the treatment makes waiting to participate in the clinical trial an inferior option for the majority of our patients.
Cultural beliefs linked to the fear of receiving an investigational drug or a placebo are commonly encountered. Also, the common conception of being treated as a “lab rat” while participating in a clinical trial usually exists as a barrier for accrual. These cultural beliefs and misconceptions have also led to under representation of racial minorities in cancer clinical trials.

- **Financial burden:**

Patients refuse to participate in the clinical trial due to the concern of the additional financial implications that might fall with the additional office visits and laboratory testing, let alone arranging transportations for those visits may create an added barrier. Additionally, the legitimate concern of having extra days off work to accommodate the clinical trial office visits and laboratory testing, adding yet another layer of financial burden.

- **Patients’ status:**

Disease burden affects the patients’ general performance status and subsequently excludes them from clinical trials. This barrier can often be counterintuitive to the patient’s ultimate well-being. As performance status limitations are often directly or indirectly related to their underlying malignancy, and in such settings, treating the underlying malignancy serves to improve their energy level and performance status. Also, comorbidities remain a common exclusion criterion.

- **Physician commitment:**

Explaining the science behind the investigational agent, its mechanism of action, and the study hypothesis as well as disclosing benefit/risk balance while incorporating the financial burden and time commitment is crucial for clinical trial screening.

Due to the level of confidence and trust built between the primary oncologist and the patients/their families, the clinical trial is best introduced and explained by the treating physician, which requires physician enthusiasm and commitment as well as open communication with the research team.

- **Clinical trials challenges in the midst of a pandemic:**

During the COVID-19 pandemic, our research staff noted continued interest in clinical trials. However, patients express concerns over multiple in-person visits required on trial. Lack of education surrounding risks of admission vs risks of immunosuppression need to be addressed. Also screen failures have become more prominent throughout the pandemic as patients delay medical care until situation is urgent. This leads to a worsened disease burden, worsened performance status, organ dysfunction which disqualifies them from participation in many clinical trials.

**Discussion And Implications For Further Research**
Identifying common obstacles for clinical trial enrollment is a key to improving the clinical trial accrual rate, therefore improving the advancement in cancer treatments (25). We explored this aspect from our research staff perspective. We aimed to identify barriers to clinical trials accrual and propose potential interventions in future trials protocols that would improve the accrual rates and facilitate patients’ enrollment and commitment in clinical trials.

The complexity of clinical trials protocol is a reported obstacle by our research coordinators and other studies (26). Clinical trial protocols that include simple schema, minimizing office visits and frequency of laboratory testing would be more feasible for patients to participate in clinical trials. If frequent laboratory testing is necessary for investigational drug monitoring, utilizing home health care services for eligible patients to perform blood draws for required laboratory testing, as well as utilizing virtual care visits to follow up on patients’ tolerance; would facilitate patients’ commitment to clinical trials and eliminate the financial burden of frequent transportation. Although industry-sponsored clinical trials offer travel reimbursement programs, having this implemented universally for all trials would also aid in recruitment.

Utilizing social workers services to help with transportation aids that are offered by patients’ primary insurance should also be considered.

Other tools to improve patients’ accrual is to broaden the eligibility criteria considering the patients’ comorbidities and performance status, as well as minimize additional biopsies required for accrual.

A language barrier is encountered by one-third of cancer patients as determined by SEER database statistics review 2000-2017. The majority of these patients are Spanish speaking, therefore having a Spanish informed consent form with every clinical trial protocol suffices as a measure that would efficiently facilitate non-English speakers to participate in clinical trials. At the same time, it demonstrates to that specific patient population that their participation in clinical trials is important in furthering cancer research.

Finally, delivering the best care for cancer patients in general as well as cancer clinical trials has been challenging through the COVID-19 pandemic. Balancing the risks of treatment procedures, its potential complications and exposure to COVID-19, using the ultimate safety measures following CDC guidelines is crucial. Re-evaluating the infrastructure of clinical trial operations by revising procedures and modifying required visits to minimize exposure should be widely implemented.

This study does not provide hard, fast or quick answers to clinical trials operations, but it does provide indications of possible directions for academic and sponsored clinical trials teams to improve the feasibility of clinical trials and bolster the potential accrual efforts that could be implemented.

**Conclusion**

This qualitative study is reporting a new perspective for barriers to clinical trials accrual, our research coordinators reported the main reasons patients failed to participate in clinical trials. The main five
themes reported clinical trials protocol, communication barriers and cultural beliefs, financial barriers, patients’ comorbidities and performance status, and physicians’ commitment. We proposed possible measures that could be implemented in clinical trial protocols.

Limitations:

- Interpretations of qualitative research are limited by our research staff’s personal experience that might influence the observations and conclusion.
- Using open ended questions for our survey, makes our participants have more control over the content of the data collected, which raises a challenges to verify our results.
- Qualitative research methodology is based on opinion and judgement of research staff rather than computed results, which eliminate the possibility to investigate causality.

Abbreviations

- NCI: National Cancer Institute
- NCI-LAPS: Lead Academic Participating Sites
- IRB: Institutional Review Board
- COVID-19: Coronavirus Disease-2019
- CDC: Centers of Disease Control

Declarations

Ethics approval and consent to participate

The research study was IRB exempt following the University of Oklahoma Office of Human Research Participant Protection: SOP 401 policies, Section 1.1, Subsection 1.1.2, Category 2.a

Consent to publish

The need for consent was deemed unnecessary following the University of Oklahoma Research Exempt form IRB Review.

The research protocol is following clinical research ethical guidelines and de-identified surveys were used for the analysis. The identity of the human participants cannot readily be ascertained, directly or through identifiers liked to the participants.

Availability of data and materials

The data that support the findings of this study are available from the corresponding author upon reasonable request.
The data is partially presented within the manuscript and table 1.

The survey was developed for this study only and has not been published elsewhere. (supplemental material 1)

**Competing interests**

Not applicable

**Funding**

Not applicable

**Authors' Contributions**

No conflict of interest has been declared by the authors.

All authors made substantial contributions to the conception and the design of the research, data analysis and interpretation.

All authors participated in drafting the work and revising it critically, and approved the final version of the manuscript to be published.

**Acknowledgements** Not applicable

**References**

1. Rimel BJ. Clinical Trial Accrual: Obstacles and Opportunities. Front Oncol. 2016;6:103.
2. Unger JM, Cook E, Tai E, Bleyer A. The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. Am Soc Clin Oncol Educ Book. 2016;35:185-98.
3. Dilts DM, Sandler AB, Cheng SK, Crites JS, Ferranti LB, Wu AY, et al. Steps and time to process clinical trials at the Cancer Therapy Evaluation Program. J Clin Oncol. 2009;27(11):1761-6.
4. Knelson LP, Cukras AR, Savoie J, Agarwal A, Guo H, Hu J, et al. Barriers to Clinical Trial Accrual: Perspectives of Community-Based Providers. Clin Breast Cancer. 2020;20(5):395-401 e3.
5. Go RS, Frisby KA, Lee JA, Mathiason MA, Meyer CM, Ostern JL, et al. Clinical trial accrual among new cancer patients at a community-based cancer center. Cancer. 2006;106(2):426-33.
6. Lara PN, Jr., Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001;19(6):1728-33.
7. Schroen AT, Petroni GR, Wang H, Gray R, Wang XF, Cronin W, et al. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials. 2010;7(4):312-21.
8. Largent EA, Lynch HF. Addressing Financial Barriers to Enrollment in Clinical Trials. JAMA Oncol. 2018;4(7):913-4.

9. Mills EJ, Seely D, Rachlis B, Griffith L, Wu P, Wilson K, et al. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol. 2006;7(2):141-8.

10. Mahmud A, Zalay O, Springer A, Arts K, Eisenhauer E. Barriers to participation in clinical trials: a physician survey. Curr Oncol. 2018;25(2):119-25.

11. Embi PJ, Jain A, Clark J, Bizjack S, Hornung R, Harris CM. Effect of a clinical trial alert system on physician participation in trial recruitment. Arch Intern Med. 2005;165(19):2272-7.

12. Denson AC, Mahipal A. Participation of the elderly population in clinical trials: barriers and solutions. Cancer Control. 2014;21(3):209-14.

13. Fern LA, Whelan JS. Recruitment of adolescents and young adults to cancer clinical trials—international comparisons, barriers, and implications. Semin Oncol. 2010;37(2):e1-8.

14. Fern LA, Taylor RM. Enhancing accrual to clinical trials of adolescents and young adults with cancer. Pediatr Blood Cancer. 2018;65(9):e27233.

15. Mouton CP, Harris S, Rovi S, Solorzano P, Johnson MS. Barriers to black women's participation in cancer clinical trials. J Natl Med Assoc. 1997;89(11):721-7.

16. Ford JG, Howerton MW, Lai GY, Gary TL, Bolen S, Gibbons MC, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer. 2008;112(2):228-42.

17. Haddad RI, Chan AT, Vermorken JB. Barriers to clinical trial recruitment in head and neck cancer. Oral Oncol. 2015;51(3):203-11.

18. Melisko ME, Hassin F, Metzroth L, Moore DH, Brown B, Patel K, et al. Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers. Clin Breast Cancer. 2005;6(1):45-54.

19. Schaeffer MH, Krantz DS, Wichman A, Masur H, Reed E, Vinicky JK. The impact of disease severity on the informed consent process in clinical research. Am J Med. 1996;100(3):261-8.

20. Hudson SV, Momperousse D, Leventhal H. Physician perspectives on cancer clinical trials and barriers to minority recruitment. Cancer Control. 2005;12 Suppl 2:93-6.

21. Benson AB, 3rd, Pregler JP, Bean JA, Rademaker AW, Eshler B, Anderson K. Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study. J Clin Oncol. 1991;9(11):2067-75.

22. Tognoni G, Alli C, Avanzini F, Bettelli G, Colombo F, Corso R, et al. Randomised clinical trials in general practice: lessons from a failure. BMJ. 1991;303(6808):969-71.

23. Thompson CB, Walker BL. Basics of research (Part 12): Qualitative research. Air Med J. 1998;17(2):65-70.

24. Annells M. Grounded theory method, Part I: Within the five moments of qualitative research. Nurs Inq. 1997;4(2):120-9.
25. Crombie IK, McMurdo ME, Irvine L, Williams B. Overcoming barriers to recruitment in health research: concerns of potential participants need to be dealt with. BMJ. 2006;333(7564):398.

26. Vastola ME, Yang DD, Muralidhar V, Mahal BA, Lathan CS, McGregor BA, et al. Laboratory Eligibility Criteria as Potential Barriers to Participation by Black Men in Prostate Cancer Clinical Trials. JAMA Oncol. 2018;4(3):413-4.

27. Somkin CP, Altschuler A, Ackerson L, Geiger AM, Greene SM, Mouchawar J, et al. Organizational barriers to physician participation in cancer clinical trials. Am J Manag Care. 2005;11(7):413-21.

28. Pinto HA, McCaskill-Stevens W, Wolfe P, Marcus AC. Physician perspectives on increasing minorities in cancer clinical trials: an Eastern Cooperative Oncology Group (ECOG) Initiative. Ann Epidemiol. 2000;10(8 Suppl):S78-84.

29. Biedrzycki BA. Research information knowledge, perceived adequacy, and understanding in cancer clinical trial participants. Oncol Nurs Forum. 2011;38(4):E291-6.

30. Petitte T, Nichols A, Narsavage G. Cultural and Environmental Enablers and Barriers to Participation and Retention in Clinical Trials for Cancer Research. EC Pulmonol Respir Med. 2019;8(9):600-6.

Tables

Table 1: Selected quotes illustrating themes and codes.
| Themes                        | Codes                                                                 | Quoted responses.                                                                                                                                 |
|------------------------------|-----------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|
| Clinical trial protocol      | - Frequent laboratory testing and office visits.                     | “Patients often find that: a) Office visits are too much b) Laboratory tests are too frequent in between office visits c) Treatment schedules interfere with their work schedule hence affecting the quality of life and preclude financial burden” |
|                              | -Treatment schedule and time commitment.                             | “Patients live too far away and would prefer a less regimented treatment which provides more logistical wiggle room”                                  |
|                              | -Strict inclusion/exclusion criteria.                                 | “Strict Inclusion/Exclusion has been the main barrier to enrollment”                                                                               |
|                              | -Additional biopsy requirements.                                      | “Mandatory tissue requirements of certain specifications often make patients reluctant to participate”                                               |
| Communication barrier and    | -Language barrier                                                     | “Patients often are not willing to try investigational drugs”                                                                                     |
| Cultural beliefs             | -Refusal to be on an investigated subject                             | “Patients decline is due to the fear of being experimented on”                                                                                   |
|                              | -Concerns about the risks with an investigational agent               | “Patients has the cultural belief that if they are on a clinical trial, they are being treated as a guinea pig or a lab rat and refuse to listen about what the trial entails” |
|                              |                                                                       | “Patients do not want to take the risk of being on placebo arm and would rather standard treatment”                                              |
|                              |                                                                       | “whenever we have not an English speaker patient, we have difficulty enrolling them on a clinical trial even if they are cooperative due to lack of foreign language informed consent” |
| Financial barriers           | - Financial burden of additional laboratory testing and office visits. | “A lot of times, patients have expectations that all treatments/procedures while on the study are provided by the study, they get quite anxious with costs of the additional laboratory testing and the transportation needed” |
|                              | - Burden of extra days off to accommodate the trial protocol          | “The fear of missing extra days off work to follow the study treatment schedule and office visits”                                                |
| Patients’ status             | -Performance status                                                  | “Most of the clinical trials limit inclusion criteria based on performance status which might be affected due to the disease burden”                |
|                              | -Comorbidities                                                       | “Declining physical condition due to disease burden excludes patients”                                                                          |
|                              |                                                                       | “Comorbidities is often what excludes patients from participating in clinical trials”                                                            |
| Physician commitment | “The physicians doing a good job of rationalizing why patients are ideal candidates for a clinical trial prior to the research nurse/coordinator going in for the consent”
| -Building a foundation of confidence. | “The physician is the person our patient most relies on to make informed decisions on their healthcare”
| -Appropriately introducing the research team. | “Building a foundation of confidence for the clinical trial and the research”

| Clinical trials challenges in the midst of a pandemic | “…have not seen a decreased interest in clinical trial enrollment throughout the pandemic”
| -Delays to seek medical attention leads to more screen failures | “Clinical trial infrastructure has been hit during the pandemic”
| -Continued interest but lacking education | “Patients seem to be more concerned about contracting COVID at the hospital than in the community”
| -Implementing telemedicine visits | “Patients are not seeking healthcare as soon as they normally would sue to the pandemic”
| | “More screen failures as patients’ diseases have progressed to the point their performance status or hepatic function is no longer compatible with clinical trial”
| | “Accommodate some telemedicine visits for trial patients as well as continue to provide them a safe face to face visit as well with universal masking, screening at every entrance and limited visitors”
| | “Re-evaluate what procedures and visits in clinical trials are “unnecessary” in hopes of minimizing the exposure risk for our patients”

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- [SurveyKerukous.pdf](#)